SecBot SecBot
SECBOTREPLAY Home › Report › RGEN

RGEN · Repligen announced a definitive agreement to acquire BioLife Solutions…

REPLIGEN CORP · 425 filed Jul 22, 2026 at 09:00 ET

At the news

BULLISHIMPACT 7/10

425 filed Jul 22, 2026 at 09:00 ET

Repligen announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal, expanding its cell therapy capabilities. The company also reported preliminary Q2 2026 revenue growth of ~12% (13% organic) and expects strong margin expansion. The transaction is expected to close in Q4 2026 and be accretive to adjusted EPS by at least $0.05 in year one.

  • Acquisition of BioLife Solutions for $11.25 cash + 0.1442 RGEN shares per BLFS share, total enterprise value ~$1.5B
  • Implied premium of 24% to 90-day VWAP
  • Expected to close in Q4 2026, subject to regulatory and BioLife shareholder approvals
  • Repligen expects at least $20M synergies in year one, $30M in year two

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access